Canis ISSN: 2398-2942

Moxidectin

Synonym(s): Advocate®, Advantage® Multi

Contributor(s): Linda Horspool

Introduction

Name

  • CAS.

Class of drug

  • A milbemycin, member of the macrocyclic lactone (macrolide) antimicrobial class.

Description

Chemical name

  • (2aE,4E,8E)-(52S,6R,62S,11R,13R,15S,17aR,20R,20aR,20bS)-62-[(1E)-1,3-dimethylbut-1-enyl]-52,62,10,11,14,15,17a,20,20a,20b-decahydro-20,20b-dihydroxy-52,6,8,19-tetramethylspiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,22-[2H]pyran]-42,17(32H,6H)-dione 42-(E)-(O-methyloxime).

Molecular formula

  • C37H53NO8

Molecular weight

  • 639.84

Physical properties

  • Water Solubility (at 25 °C, pH 7): 51 ppb.
  • Octanol-water Partition Coefficient: 58.3.
  • Photolysis half-life: 6.8 hours.
  • Finished product:
    • Spot-on solution.
    • A clear, yellow to brownish solution.

Storage requirements

  • Product as packaged for sale: Do not store above 30 °C.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Endectocide - activity against endo- and ectoparasites.
  • Broad spectrum of activity in dogs, cats and ferrets including:
    • Gastrointestinal nematodes.
    • Developmental stages of filarial nematodes (egDirofilaria immitis Dirofilaria immitis ).
    • Arachnids, such as mites.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • No other antiparasitic macrocyclic lactone should be administered concurrently.
  • No interactions with routinely used veterinary medicinal products or medical or surgical procedures have been observed.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references fromVetMedResourceandPubMed.
  • Traversa D, Mazzi A, Di Cesare A, Famigli Bergamini P, Fracassi F, Fanini G, Aste G, Pampurini F, Boari A (2013)Potential efficacy of monthly administrations of spot-on moxidectin 2.5 %/imidacloprid 10 % in the simultaneous prevention of major canine filarioses.Parasitol Res112, 3753-3756PubMed.
  • Austin CM, Kok DJ, Crafford D, Schaper R (2013)The efficacy of a topically applied imidacloprid 10 % / moxidectin 2.5 % formulation (Advocate®, Advantage® Multi, Bayer) against Immature and Adult Spirocerca lupi worms in experimentally infected dogs.Parasitol Res112Suppl 1, 91-108PubMed.
  • Janko C, Geyer J (2013)Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin.J Vet Pharmacol Ther36, 275-284PubMed.
  • Taweethavonsawat P, Chungpivat S, Watanapongchati S, Traub RJ, Schaper R (2012)Efficacy of a spot on combination containing imidacloprid 10% and moxidectin 1% (Advocate(®)/Advantage(®) Multi, Bayer Animal Health) against Ancylostoma ceylanicum in cats.Vet Parasitol190, 289-293PubMed.
  • Fourie JJ, Delport PC, Fourie LJ, Heine J, Horak IG, Krieger KJ (2009)Comparative efficacy and safety of two treatment regimens with a topically applied combination of imidacloprid and moxidectin (Advocate) against generalised demodicosis in dogs.Parasitol Res105Suppl 1, S115-124PubMed.
  • Paterson TE, Halliwell RE, Fields PJ, Louw ML, Louw JP, Ball GS, Pinckney RD, McKibben JS (2009)Treatment of canine-generalized demodicosis: a blind, randomized clinical trial comparing the efficacy of Advocate(Bayer Animal Health) with ivermectin.Vet Dermatol20, 447-455PubMed.
  • Heine J, Krieger K, Dumont P, Hellmann K (2005)Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of generalized demodicosis in dogs: results of a European field study.Parasitol Res97Suppl 1, S89-96PubMed.
  • Arther RG, Bowman DD, Slone RL, Travis LE (2005)Imidacloprid plus moxidectin topical solution for the prevention of heartworm disease (Dirofiloria immitis) in dogs.Parasitol Res97Suppl 1,S76-80PubMed.
  • Bianciardi P, Otranto D (2005)Treatment of dog thelaziosis caused by Thelazia callipaeda (Spirurida, Thelaziidae) using a topical formulation of imidacloprid 10% and moxidectin 2.5%.Vet Parasitol129, 89-93PubMed.
  • Krieger K, Heine J, Dumont P, Hellmann K (2005)Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study.Parasitol Res97Suppl 1, S81-88PubMed.
  • Paul AJ, Hutchens DE, Firkins LD, Borgstrom M. (2004)Dermal safety study with imidacloprid/moxidectin topical solution in the ivermectin-sensitive collie.Vet Parasitol121, 285-291PubMed.
  • Hellmann K, Knoppe T, Radeloff I, Heine J (2003)The anthelmintic efficacy and the safety of a combination of imidacloprid and moxidectin spot-on in cats and dogs under field conditions in Europe.Parasitol Res90Suppl 3, S142-143PubMed.
  • von Samson-Himmelstjerna G, Epe C, Schimmel A, Heine J (2003)Larvicidal and persistent efficacy of an imidacloprid and moxidectin topical formulation against endoparasites in cats and dogs.Parasitol Res90Suppl 3, S114-115PubMed.

Other sources of information


ADDED